HDAC9 and breast carcinoma: As a proof-of-concept, we show that this metastatic breast cancer cell-of-origin signature can be synergistically targeted with HDAC and HSP90 inhibitors combined with Niclosamide in sixteen out of seventeen breast cancer cell lines.